Inventiva S.A. (IVA) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Inventiva Sa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.009 -- 00:00:04.051 Thank you, good morning, good afternoon, everybody, and thanks for joining us today for 00:00:04.051 -- 00:00:05.932 this webcast. 00:00:05.932 -- 00:00:08.353 Before we begin, as usual, 00:00:08.353 -- 00:00:12.675 I ask you to please read the disclaimer on slide two, which should appear now, and I 00:00:12.675 -- 00:00:17.777 want to remind everyone that the various statements that we may make during today's 00:00:17.777 -- 00:00:22.599 conference or during the Q&A session will include forward-looking statements within the 00:00:22.599 -- 00:00:25.721 meaning of the Private Securities Litigation Reform Act of 1995. 00:00:25.721 -- 00:00:28.421 Today, in this call, 00:00:29.352 -- 00:00:34.594 I'm joined by Jean, Jean Boulatier, our CFO, and by our CFO 00:00:34.594 -- 00:00:37.175 and co-founder, Pierre Broca. 00:00:37.175 -- 00:00:40.236 So let me go back to some of the highlights 00:00:40.236 -- 00:00:42.236 of 00:00:42.838 -- 00:00:47.079 Lani Fiber Nord development program by starting by 1983. 00:00:47.079 -- 00:00:49.080 So in January 23, 00:00:49.080 -- 00:00:54.142 we announced some important changes to the design of the phase three, evaluating 00:00:54.142 -- 00:00:57.014 Lani inpatient with MASH-NASH. 00:00:57.014 -- 00:01:02.656 which made the study more attractive for the site and especially more patient-friendly. 00:01:02.656 -- 00:01:08.237 This new design is based on discussion we had with the FDA and on the alternative approach 00:01:08.237 -- 00:01:13.879 put forward by the US FDA, which includes two independent phase three, 00:01:13.879 -- 00:01:18.980 one based on histological outcomes, native three, which would allow us, if 00:01:18.980 -- 00:01:23.162 our results are positive, to fight for accelerated approval....